Evidence map›Paper›PMID 20375787›Full record

ReviewCurrent opinion in pulmonary medicine2010

Urine for the diagnosis of tuberculosis: current approaches, clinical applicability, and new developments.

Jonathan Peter, Clare Green, Michael Hoelscher, Peter Mwaba, Alimuddin Zumla, Keertan Dheda

Open access · greenAbstract readReview
In one paragraph

Review in Current opinion in pulmonary medicine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed, 7 pooled it
9.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

60 citing papers in PubMed, 7 syntheses or guidelines pooled it, 113 citations in OpenAlex.

  1. Pooled it
  2. XpertThe Cochrane database of systematic reviews · 2018
    Pooled it
  3. Guideline
  4. Pooled it
  5. Pooled it
  6. Diagnostic accuracy of nucleic acid amplification tests in urine for pulmonary tuberculosis: a meta-analysis.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2015
    Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Article
  13. Lateral flow urine lipoarabinomannan assay for tuberculosis diagnosis in HIV-positive inpatients and outpatients.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia · 2025
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 3 countries.

Jonathan PeterLung Infection and Immunity Unit, Division of Pulmonology and Clinical Immunology and UCT Lung Institute, Department of Medicine, University of Cape Town, Cape Town, South Africa.
Clare Green
Michael Hoelscher
Peter Mwaba
Alimuddin Zumla
Keertan Dheda
University College London · GBNational Institute for Medical Research · TZSouth African Tuberculosis Vaccine Initiative · ZAUniversity of Cape Town · ZA

Funding

Fogarty International Clinical Research Scholars Support Center @ Vanderbilt-AAMCR24TW007988 · FIC · VANDERBILT UNIVERSITY · PI VERMUND, STEN H. · 2007 to 2011
$27.6M
FIC NIH HHS R24 TW007988FIC NIH HHS R24TW007988Medical Research Council
6 · The paper itself

Abstract

purpose of reviewUrine is increasingly being investigated as a convenient clinical sample for the identification of mycobacterial products for the diagnosis of tuberculosis. The available literature on mycobacterial lipoarabinomannan (LAM) and urine mycobacterial DNA is reviewed. RECENT

findingsThe available data, despite being extracted from heterogeneous clinical populations and different clinical subgroups, indicate that urine LAM has little diagnostic utility in unselected tuberculosis suspects; however, test characteristics improve in HIV-infected patients, particularly those with advanced immunosuppression (CD4 cell count <200 cells/microl). Methodologies for urine PCR for detection of mycobacterial DNA vary across studies and focus is on standardizing assays with respect to specimen collection, assay design, and processing methodology. SUMMARY: Both the urine LAM and PCR for mycobacterial DNA are being evaluated in different geographical settings. Urine LAM currently offers little utility for the diagnosis of tuberculosis in unselected populations. However, urine LAM appears promising as a diagnostic tool in HIV-infected patients with CD4 cell counts less than 200 cells/microl in different clinical settings. Further developmental studies are required to enhance the performance of the assays, and their usefulness over sputum microscopy in HIV-infected patients with advanced immunosuppression requires definition in large cohort studies.

Indexed as

DNA, BacterialForecastingHumansLipopolysaccharidesMaleMycobacterium tuberculosisPolymerase Chain ReactionSensitivity and SpecificitySeverity of Illness IndexTuberculosisTuberculosis, PulmonaryUrinalysisUrineDNA, BacteriallipoarabinomannanLipopolysaccharides

Identifiers

PMID20375787
PMCPMC5454484
OpenAlexW2158575592

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.